Institut Pasteur

Centre National De La Recherche Scientifique

Boehringer Ingelheim Vetmedica Gmbh

Yves Jacob

Pierre Perrin

Chokri Bahloul

Frédéric Tangy

Noël Tordo

Pierre Charneau

Chaouki Miled

Thierry Rose

No&euml;l Tordo

Sophie Goyard

Vincent Hervin

Glwadys Gagnot

Yves-Louis Janin

Eloi Paul Coutant

The present invention is in the field of bioluminescence in biology and/or medicine. In particular, the invention provides imidazopyrazine derivatives, processes for preparation thereof, and their uses as luciferins.

Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins

The present invention relates to a methodology for the generation of infectious ribonucleoparticles (RNPs) of negative-strand RNA viruses, and in particular of non-segmented negative-strand RNA viruses in yeast, especially in budding yeast. Accordingly, the patent application relates to a recombinant yeast strain suitable for the rescue of infectious non-segmented negative-strand RNA virus particles or infectious virus-like particles. The invention also relates to the use of the recombinant yeast to prepare vaccine seed and to the use of the produced RNPs or RNPs-like to prepare vaccine formulations. It also concerns the use of the recombinant yeast for the screening of libraries of DNA.

Reverse genetics of negative-strand RNA viruses in yeast

The present invention relates to recombinant cells as well as to methods for the generation of non-segmented negative-sense single-stranded RNA viruses (NNV or mononegavirales) from cloned deoxyribonucleic acid (cDNA), especially from measles virus and in particular from attenuated strains such as those approved for vaccination, in particular from the attenuated Schwarz measles virus and various recombinant Schwarz measles-based viruses expressing heterologous sequences. Such rescued viruses can be used, after amplification, as vaccines for immunization against measles and/or against the heterologous peptides or proteins expressed.

Cells and methodology to generate non-segmented negative-strand RNA  viruses

Cells and methodology to generate non-segmented negative-strand RNA viruses

The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of a lyssavirus glycoprotein, which has been found to improve the immunogenicity of lyssavirus epitopes for protection from rabies. The chimeric nucleic acids and proteins can also contain antigenic determinants for epitopes other than those of lyssavirus. Thus, the invention provides chimeric nucleic acids and polypeptides that elicit a strong immune response to multiple antigens. Use of the methods of the present invention permits DNA vaccination without the need to supply multiple antigens on separate DNA molecules.

Chimeric lyssavirus nucleic acids and polypeptides

The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of aglycoprotein, which has been found to improve the immunogenicity ofepitopes for protection from rabies. The chimeric nucleic acids and proteins can also contain antigenic determinants for epitopes other than those of. Thus, the invention provides chimeric nucleic acids and polypeptides that elicit a strong immune response to multiple antigens. Use of the methods of the present invention permits DNA vaccination without the need to supply multiple antigens on separate DNA molecules.

The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode at least site III of a lyssavirus glycoprotein.

Growing community of inventors

Maintenon, France

Yves Jacob